C. Romeo

发表

Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network

D. Berton, P. Colombo, I. Treilleux, 2022, Cancers.

Pembrolizumab and Chemotherapy in Cervical Cancer: A New Standard of Care?

I. Ray-Coquard, B. Méry, O. Saux, 2022, Oncology & Haematology.

Rare ovarian tumors: an update on diagnosis and treatment

I. Ray-Coquard, H. Vanacker, C. Romeo, 2020, International Journal of Gynecological Cancer.

Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database

R. Rouzier, I. Ray-Coquard, A. Floquet, 2022, Cancers.

Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.

E. Blot, I. Ray-Coquard, E. Kalbacher, 2019, Gynecologic oncology.

Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?

I. Ray-Coquard, H. Vanacker, C. Romeo, 2019, Current opinion in oncology.

Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study.

C. Genestie, D. Berton, F. Guyon, 2023, Gynecologic oncology.

EP967 Natural history of patients with BRCA-mutated high grade epithelial ovarian cancer (HGEOC) before the era of PARP inhibitors maintenance in 1st line treatment

R. Rouzier, T. Petit, I. Ray-Coquard, 2019, International Journal of Gynecological Cancer.

Gynecological carcinosarcomas: Overview and future perspectives.

C. Romeo, A. Buisson, P. Meeus, 2023, Bulletin du Cancer.